NSTI Accessory Mutations:			Non	None			
N Other Mutations:			R20	R20K • T112A • T124A • T125TM			
Integrase Strand Transfer Inhibitors							
nictegravir (BIC)			Pote	Potential Low-Level Resistance			
abotegravir (CAB)			Low	Low-Level Resistance			
dolutegravir (DTG)			Pote	Potential Low-Level Resistance			
elvitegravir (EVG)			High	High-Level Resistance			
altegravir (RAL)			Inter	Intermediate Resistance			
N comments							
Major							
E92Q is a common non-polymorphic mutation selected in persons rec							
This virus is predicted to have low-level reduced susceptibility to CAB							
Mutation	scoring: IN	ı					
Orug resistance mutation scores of INSTI:				Download C5V			
Rule	BIC ÷	CAB ≑	DTG ÷	EVG ≑	RAL ≑		
E920	10	15	10	60	30		
						1	

Drug resistance interpretation: IN

INSTI Major Mutations:

Resistance Resistance n persons receiving RAL and EVG. It reduces RAL susceptibility 5 to 10-fold and EVG susceptibility ~30-fold. It does not reduce susceptibility to BIC, CAB, and DTG. ibility to CAB. The use of the combination of CAB/RPV should be considered to be relatively contraindicated. HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)